Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Efficacy and Safety of Hypofractionated Radiotherapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme: A Systematic Review and Meta-Analysis.

Liao G, Zhao Z, Yang H, Li X.

Front Oncol. 2019 Oct 14;9:1017. doi: 10.3389/fonc.2019.01017. eCollection 2019.

2.

Radiotherapy for diffuse brainstem glioma in children and young adults.

Hu X, Fang Y, Hui X, Jv Y, You C.

Cochrane Database Syst Rev. 2016 Jun 27;(6):CD010439. doi: 10.1002/14651858.CD010439.pub2. Review.

PMID:
27378212
3.

Antiangiogenic therapy for high-grade glioma.

Khasraw M, Ameratunga MS, Grant R, Wheeler H, Pavlakis N.

Cochrane Database Syst Rev. 2014 Sep 22;(9):CD008218. doi: 10.1002/14651858.CD008218.pub3. Review. Update in: Cochrane Database Syst Rev. 2018 Nov 22;11:CD008218.

PMID:
25242542
4.

Temozolomide for high grade glioma.

Hart MG, Garside R, Rogers G, Stein K, Grant R.

Cochrane Database Syst Rev. 2013 Apr 30;(4):CD007415. doi: 10.1002/14651858.CD007415.pub2. Review.

5.

External beam radiation dose escalation for high grade glioma.

Khan L, Soliman H, Sahgal A, Perry J, Xu W, Tsao MN.

Cochrane Database Syst Rev. 2016 Aug 19;(8):CD011475. doi: 10.1002/14651858.CD011475.pub2. Review.

PMID:
27541334
6.

Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant neoplasms, overall and progression-free survival: individual participant data analysis.

Franklin J, Eichenauer DA, Becker I, Monsef I, Engert A.

Cochrane Database Syst Rev. 2017 Sep 13;9:CD008814. doi: 10.1002/14651858.CD008814.pub2. Review.

7.

Hypofractionated accelerated radiotherapy (HART) with concurrent and adjuvant temozolomide in newly diagnosed glioblastoma: a phase II randomized trial (HART-GBM trial).

Mallick S, Kunhiparambath H, Gupta S, Benson R, Sharma S, Laviraj MA, Upadhyay AD, Julka PK, Sharma D, Rath GK.

J Neurooncol. 2018 Oct;140(1):75-82. doi: 10.1007/s11060-018-2932-3. Epub 2018 Jun 23.

PMID:
29936695
8.

Progression-Free but No Overall Survival Benefit for Adult Patients with Bevacizumab Therapy for the Treatment of Newly Diagnosed Glioblastoma: A Systematic Review and Meta-Analysis.

Kaka N, Hafazalla K, Samawi H, Simpkin A, Perry J, Sahgal A, Das S.

Cancers (Basel). 2019 Nov 4;11(11). pii: E1723. doi: 10.3390/cancers11111723. Review.

9.

Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.

Zhu J, Li R, Tiselius E, Roudi R, Teghararian O, Suo C, Song H.

Cochrane Database Syst Rev. 2017 Dec 16;12:CD011300. doi: 10.1002/14651858.CD011300.pub2. Review.

10.

Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

Sbidian E, Chaimani A, Garcia-Doval I, Do G, Hua C, Mazaud C, Droitcourt C, Hughes C, Ingram JR, Naldi L, Chosidow O, Le Cleach L.

Cochrane Database Syst Rev. 2017 Dec 22;12:CD011535. doi: 10.1002/14651858.CD011535.pub2. Review.

11.

The role of Gliadel wafers in the treatment of newly diagnosed GBM: a meta-analysis.

Xing WK, Shao C, Qi ZY, Yang C, Wang Z.

Drug Des Devel Ther. 2015 Jun 29;9:3341-8. doi: 10.2147/DDDT.S85943. eCollection 2015. Review.

12.

Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme.

Jastaniyah N, Murtha A, Pervez N, Le D, Roa W, Patel S, Mackenzie M, Fulton D, Field C, Ghosh S, Fallone G, Abdulkarim B.

Radiat Oncol. 2013 Feb 20;8:38. doi: 10.1186/1748-717X-8-38.

13.

Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early stage Hodgkin lymphoma.

Blank O, von Tresckow B, Monsef I, Specht L, Engert A, Skoetz N.

Cochrane Database Syst Rev. 2017 Apr 27;4:CD007110. doi: 10.1002/14651858.CD007110.pub3. Review.

14.

Positron emission tomography-adapted therapy for first-line treatment in individuals with Hodgkin lymphoma.

Sickinger MT, von Tresckow B, Kobe C, Engert A, Borchmann P, Skoetz N.

Cochrane Database Syst Rev. 2015 Jan 9;1:CD010533. doi: 10.1002/14651858.CD010533.pub2. Review.

PMID:
25572491
16.

Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction: A Systematic Review and Meta-analysis.

Dhakal B, Szabo A, Chhabra S, Hamadani M, D'Souza A, Usmani SZ, Sieracki R, Gyawali B, Jackson JL, Asimakopoulos F, Hari PN.

JAMA Oncol. 2018 Mar 1;4(3):343-350. doi: 10.1001/jamaoncol.2017.4600.

17.

The Role of a Single Angiogenesis Inhibitor in the Treatment of Recurrent Glioblastoma Multiforme: A Meta-Analysis and Systematic Review.

Wang Y, Xing D, Zhao M, Wang J, Yang Y.

PLoS One. 2016 Mar 23;11(3):e0152170. doi: 10.1371/journal.pone.0152170. eCollection 2016. Review.

18.

Oral versus intravenous fluoropyrimidines for colorectal cancer.

Chionh F, Lau D, Yeung Y, Price T, Tebbutt N.

Cochrane Database Syst Rev. 2017 Jul 28;7:CD008398. doi: 10.1002/14651858.CD008398.pub2. Review.

19.

Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial.

Malmström A, Grønberg BH, Marosi C, Stupp R, Frappaz D, Schultz H, Abacioglu U, Tavelin B, Lhermitte B, Hegi ME, Rosell J, Henriksson R; Nordic Clinical Brain Tumour Study Group (NCBTSG).

Lancet Oncol. 2012 Sep;13(9):916-26. Epub 2012 Aug 8.

PMID:
22877848
20.

Phase 2 Study of Bortezomib Combined With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Safety and Efficacy Assessment.

Kong XT, Nguyen NT, Choi YJ, Zhang G, Nguyen HN, Filka E, Green S, Yong WH, Liau LM, Green RM, Kaprealian T, Pope WB, Nghiemphu PL, Cloughesy T, Lassman A, Lai A.

Int J Radiat Oncol Biol Phys. 2018 Apr 1;100(5):1195-1203. doi: 10.1016/j.ijrobp.2018.01.001. Epub 2018 Jan 6. Erratum in: Int J Radiat Oncol Biol Phys. 2019 Apr 1;103(5):1289.

Supplemental Content

Support Center